AI in Cardiology and Neurotech in Focus at MedTech World North America 2026
How close are cardiovascular technologies and neurotech to changing everyday clinical care? That question will be at the heart of conversations during MedTech World North America | West Palm Beach 2026, where innovators, clinicians, and investors will meet from 11 to 13 May at the Hilton West Palm Beach.
If you want to partecipate please use the discount code: MTWDISTUSA2026 on the ticket page: https://tickets.med-tech.world/medtechworld-usa-2026
Among the highlights of the agenda is the newly introduced “Focus Panel” Series, a format designed to create more concentrated conversations around high-impact sectors.
A Closer Look at Cardio Innovation
Cardiovascular disease remains one of the leading health challenges worldwide, but technological advances are rapidly changing how care is delivered. Artificial intelligence, remote monitoring, and integrated digital health platforms are opening new possibilities for earlier detection and continuous care.
Recent market data highlights the scale of this momentum. According to market analysis, the global AI in cardiology market was valued at USD 1.69 billion in 2025 and is expected to grow to USD 14.83 billion by 2033, reflecting a compound annual growth rate (CAGR) of 31.17% between 2026 and 2033. North America continues to lead this space, accounting for 46.79% of the market in 2025.
This growth is being driven by several factors, including advances in artificial intelligence and machine learning, rising demand for early and accurate diagnosis, increasing prevalence of cardiovascular disease, and strategic initiatives from both startups and established companies.
These developments will form the foundation of the Focus Panel titled ‘From Hospital to Home: The Cardio Care Continuum.’
The discussion will explore how cardiovascular care is evolving beyond traditional clinical settings. Speakers will examine how remote monitoring technologies, integrated care pathways, and reimbursement-ready digital models are enabling a more connected healthcare ecosystem.
The panel will feature voices from across the cardiology innovation ecosystem, including Maulik Majmudar, Co-Founder & Chief Medical Officer at Biofourmis; Dr David Albert, Founder & Chief Medical Officer at AliveCor; and Homer Quintana, Director of the Center for Rapid Device Translation at Houston Methodist. Their combined experience across digital health, diagnostics, and clinical implementation will bring practical insight into how new technologies are being integrated into patient care.
Homer Quintana, Director, Center for Rapid Device Translation, Houston Methodist: “I am excited to participate in a multi-faceted panel which explores how integrated medical devices in the areas of heart and brain are not just evolving, they are redefining human health. It takes honest dialogue and collaborative validation to accelerate medical innovation. By focusing on the real-world impact we ensure those technologies solve genuine patient needs rather than innovating for innovation’s sake.”
Here for more informations: AI In Cardiology Market Size & Share | Industry Report, 2033
Neurotech: From Breakthroughs to Real-World Adoption
Alongside cardio innovation, neurotechnology will take a prominent place in the Focus Panel Series. From brain-computer interfaces to advanced diagnostic tools and neuromodulation therapies, neurotech continues to expand the boundaries of medical possibility.
The momentum in this sector is reflected in strong market projections. The global neurotech devices market, valued at USD 15.2 billion in 2024, is projected to reach USD 30.3 billion by 2030, growing at a CAGR of 12.2%.
However, while scientific progress in neurotechnology is accelerating, translating innovation into clinical practice remains complex. Companies must navigate validation studies, regulatory pathways, funding requirements, and clinical adoption hurdles before solutions can reach patients.
These realities will inform the second Focus Panel: ‘Scaling Neuro Innovation: Capital, Clinical Adoption & Corporate Pathways’
This session will explore the journey from early-stage research to large-scale adoption. The conversation will focus on how companies can align clinical evidence, regulatory readiness, investment, and corporate partnerships to move promising technologies forward.
Among the speakers joining this discussion are Christian Espinosa, Founder and CEO of Blue Goat Cyber, and Brad Maruca, Managing Director at Deloitte, who will share perspectives on security, adoption, and the broader commercial path for neurotechnology.
Christian Espinosa, Founder and CEO, Blue Goat Cyber: “I’m looking forward to the neurotech conversations at MedTech World USA 2026 because connected brain devices raise the stakes on cybersecurity and patient safety. The industry needs straight talk on building security into the design from day one so neurotech can scale with trust.”
Brad Maruca, Managing Director, Deloitte: “Neurotech is entering a pivotal phase, and I’m looking forward to discussing what it will take to build lasting trust and adoption. My view: the winners will be the companies that pair innovation with patient-centered access, real-world evidence, and long-term outcome support, while also proving value clearly enough to earn better reimbursement. That is how we turn promising science into meaningful, scalable care.”
Creating Space for Deeper Industry Dialogue
The Focus Panel Series represents a new format within the MedTech World programme, designed to provide more concentrated discussions around high-impact sectors. By narrowing the lens on specific therapeutic areas, the sessions aim to create meaningful exchanges between those developing new technologies and those responsible for adopting them.
With its mix of expert-led discussions, startup showcases, and networking opportunities, MedTech World North America | West Palm Beach 2026 will serve as a platform for exploring how innovation is being translated into real healthcare solutions.
As the global MedTech ecosystem continues to evolve, the conversations taking place in West Palm Beach this May are set to address some of the most pressing questions in the industry today: how emerging technologies can move beyond promising concepts and become tools that clinicians and patients rely on every day.
For innovators, investors, and healthcare leaders working in cardiovascular technologies and neurotechnology, the event extends an opportunity to connect with peers, exchange insights, and contribute to discussions around these rapidly advancing sectors.